Merck has opened a new manufacturing plant in Durham, NC which will make HPV vaccines, including its quadrivalent vaccine Gardasil and nine-valent vaccine Gardasil 9 … ...
Merck has opened a $1 billion, 225,000-square-foot facility at its Durham campus dedicated to vaccine manufacturing, the drug giant announced Tuesday. Merck has opened a $1 billion, 225,000-square ...
(Reuters) -Merck said on Tuesday it has opened a $1-billion facility at its North Carolina site, as the drugmaker seeks to boost its U.S. manufacturing in the face of President Donald Trump's ...
DURHAM, N.C.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today the opening of a new, $1 billion, 225,000-square-foot facility dedicated to ...
Opening highlights effort to expand U.S. manufacturing through a $1 billion investment DURHAM, N.C., March 11, 2025--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States ...
March 11 (Reuters) - A federal judge ruled in favor of Merck (MRK.N), opens new tab in litigation accusing it of concealing the risks of Gardasil, a vaccine to prevent cervical and other cancers ...
March 11 (Reuters) - Merck (MRK.N), opens new tab said on Tuesday it has opened a $1-billion facility at its North Carolina site, the latest drugmaker to boost its U.S. manufacturing amid ...
Singapore, the world’s largest bunker hub for ships, has launched a new standard for methanol bunkering, the Maritime and Port Authority of Singapore (MPA) said on Monday. The move is aimed at ...
Shipping group CMA CGM received its first ever delivery of a dual-fuel methanol vessel, with 11 more expected to arrive over the next two years. CMA CGM described the delivery of the first dual-fuel ...
Both Merck & Co. and Halozyme are holding their ground in a freshly unveiled patent dispute surrounding the New Jersey pharma’s under-the-skin version of its blockbuster cancer drug Keytruda.
Pharmaceutical giant Merck may build a $900 million manufacturing facility near Greenville. The state of Delaware has offered Merck a $30.2 million grant to encourage the company to choose the ...
One of Merck KGaA’s leading immunology assets has flunked the latest part of a phase 2 lupus trial. Despite the primary endpoint miss, Merck has concluded further development is warranted in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback